Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 18,819 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · derivative · entry 11 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,819 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 14,114 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · derivative · entry 10 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,114 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 1,100 | $385.59 | $424,150.98 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.415 to $385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 1,900 | $384.15 | $729,888.42 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,418 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $383.93 to $384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 3,700 | $382.60 | $1,415,635.91 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,318 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.26 to $383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 2,900 | $381.52 | $1,106,394.95 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,018 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.095 to $382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 12,833 | $380.50 | $4,882,918.00 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,918 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.065 to $381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 4,500 | $379.62 | $1,708,312.05 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,751 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.03 to $380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 6,000 | $378.29 | $2,269,722.60 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,251 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.00 to $378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 18,819 | $106.59 | $2,005,917.21 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:24 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 14,114 | $106.59 | $1,504,411.26 |
DisclosureSEC source: 0000914190-21-000037 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:42 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 20,000 | $344.00 | $6,880,000.00 |
DisclosureSEC source: 0000914190-21-000014 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,269 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2020. F2 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · derivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,942 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,009 | $334.98 | $672,983.26 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.81 to $335.61, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 3,990 | $334.39 | $1,334,218.89 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,146 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.79 to $334.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,501 | $333.23 | $833,415.23 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,136 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.79 to $333.73, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 700 | $331.61 | $232,126.58 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,637 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.06 to $332.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 400 | $330.27 | $132,106.00 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,337 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.06 to $330.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 400 | $328.68 | $131,472.36 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,737 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.46 to $329.38, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:18 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000012 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:28 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 5,000 | $308.00 | $1,540,000.00 |
DisclosureSEC source: 0000914190-20-000444 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,269 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,857 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,857 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 938 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,538 Underlying: Common Stock · 938 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 707 | $302.82 | $214,092.68 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.70 to $302.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 6,783 | $302.15 | $2,049,475.99 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,831 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.65 to $302.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 3,367 | $301.32 | $1,014,557.57 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,614 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.65 to 301.64, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 938 | $106.59 | $99,981.42 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 10,857 | $106.59 | $1,157,247.63 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:29 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0000914190-20-000424 · edgar.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:29 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 5,000 | $303.34 | $1,516,675.00 |
DisclosureSEC source: 0000914190-20-000424 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:29 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 5,000 | $66.90 | $334,500.00 |
DisclosureSEC source: 0000914190-20-000424 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,137 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · derivative · entry 11 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,196 Underlying: Common Stock · 9,137 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,100 | $307.78 | $338,554.59 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.54 to $308.075, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 6,291 | $306.93 | $1,930,873.98 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,237 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.51 to $307.505, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 7,391 | $106.59 | $787,806.69 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 21:36 UTC Amendment |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,391 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-20-000405 · edgar.xml · derivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,942 Underlying: Common Stock · 7,391 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This amendment is being filed solely to correct a typographical error in the number of shares exercised. F1 · derivative.exercise_date: Fully exercisable. F2 · derivative.underlying_shares: This amendment is being filed solely to correct a typographical error in the number of shares exercised. F2 · balance_after: This amendment is being filed solely to correct a typographical error in the number of shares exercised. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,600 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · derivative · entry 10 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,333 Underlying: Common Stock · 3,600 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 300 | $312.58 | $93,774.99 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.38 to $312.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,002 | $311.60 | $312,221.20 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,437 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.24 to $311.88, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,098 | $310.55 | $340,987.30 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,439 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.13 to $311.09, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 100 | $307.74 | $30,774.00 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,537 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $307.74 to $307.74, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,100 | $306.81 | $337,493.97 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.50 to $307.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 23:59 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 3,600 | $106.59 | $383,724.00 |
DisclosureSEC source: 0000914190-20-000403 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 19, 2020 17:27 UTC |
Seth AlpnaDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-20-006793 · primarydocument.xml · derivative · entry 6 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable Read SEC document |
| November 09, 2020 Filed Nov 19, 2020 17:27 UTC |
Seth AlpnaDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-20-006793 · primarydocument.xml · derivative · entry 5 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable Read SEC document |
| November 09, 2020 Filed Nov 19, 2020 17:27 UTC |
Seth AlpnaDirector
|
SaleCommon Stock | 3,665 | $306.95 | $1,124,971.75 |
DisclosureSEC source: 0001562180-20-006793 · primarydocument.xml · nonDerivative · entry 4 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,139 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.84 to $307.26, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 19, 2020 17:27 UTC |
Seth AlpnaDirector
|
SaleCommon Stock | 1,358 | $305.74 | $415,194.92 |
DisclosureSEC source: 0001562180-20-006793 · primarydocument.xml · nonDerivative · entry 3 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.72 to $305.79, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 19, 2020 17:27 UTC |
Seth AlpnaDirector
|
Exercise / conversionCommon Stock | 3,125 | $125.05 | $390,781.25 |
DisclosureSEC source: 0001562180-20-006793 · primarydocument.xml · nonDerivative · entry 2 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 19, 2020 17:27 UTC |
Seth AlpnaDirector
|
Exercise / conversionCommon Stock | 1,898 | $179.84 | $341,336.32 |
DisclosureSEC source: 0001562180-20-006793 · primarydocument.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:04 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 25,157 | $0.00 Strike: $86.25 | $0.00 |
DisclosureSEC source: 0000914190-20-000399 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,157 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.